Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 20, 2024 - Issue 1
Submit an article Journal homepage
798
Views
0
CrossRef citations to date
0
Altmetric
Coronavirus

SARS-CoV-2 seroprevalence among healthcare workers in a highly vaccinated Japanese medical center from 2020–2023

Yan Yana Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, JapanView further author information
,
Kanami Itob Department of Safety and Health Promotion, Juntendo University, Tokyo, JapanView further author information
,
Hiroshi Fukudaa Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan;b Department of Safety and Health Promotion, Juntendo University, Tokyo, JapanView further author information
,
Shuko Nojiric Medical Technology Innovation Center, Juntendo University, Tokyo, JapanView further author information
,
Wataru Urasakid Clinical Research and Trial Center, Juntendo University, Tokyo, Japan;e Graduate School of Science and Technology, Tokyo University of Science, Tokyo, JapanView further author information
,
Takamasa Yamamotof Department of Clinical Laboratory, Juntendo University Hospital, Tokyo, JapanView further author information
,
Yuki Horiuchig Department of Clinical Laboratory Medicine, Juntendo University Faculty of Medicine, Tokyo, JapanView further author information
,
Satoshi Horih Infection Control Science, Juntendo University Graduate School of Medicine, Tokyo, JapanView further author information
,
Kazuhisa Takahashii Department of Respiratory Medicine, Juntendo University Faculty of Medicine, Tokyo, JapanView further author information
,
Toshio Naitoa Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan;b Department of Safety and Health Promotion, Juntendo University, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1646-9930View further author information
ORCID Icon &
Yoko Tabef Department of Clinical Laboratory, Juntendo University Hospital, Tokyo, Japan;g Department of Clinical Laboratory Medicine, Juntendo University Faculty of Medicine, Tokyo, JapanView further author information
 show all
Article: 2337984 | Received 06 Dec 2023, Accepted 28 Mar 2024, Published online: 15 Apr 2024

References

  • United Nations. WHO chief declares end to COVID-19 as a global health emergency. [accessed 2023 Feb 12]. https://news.un.org/en/story/2023/05/1136367.
  • World Health Organization. COVID-19 epidemiological update – 16 February 2024. [accessed 2024 Feb 12]. https://www.who.int/publications/m/item/covid-19-epidemiological-update-16-february-2024.
  • Burki TK. Testing for COVID-19. Lancet Respir Med. 2020;8(7):63–6. doi:10.1016/S2213-2600(20)30247-2.
  • Ministry of Labour. Health and welfare, Japan. Policy changes after COVID-19 becomes a category V infectious disease. [accessed 2023 Aug 19]. [in Japanese]. https://www.mhlw.go.jp/stf/corona5rui.html.
  • Arashiro T, Arai S, Kinoshita R, Otani K, Miyamoto S, Yoneoka D, Kamigaki T, Takahashi H, Hibino H, Okuyama M, et al. National seroepidemiological study of COVID-19 after the initial rollout of vaccines: before and at the peak of the Omicron-dominant period in Japan. Influenza Other Respir Viruses. 2023;17(2):e13094. doi:10.1111/irv.13094.
  • Kinoshita R, Arashiro T, Kitamura N, Arai S, Takahashi K, Suzuki T, Suzuki M, Yoneoka D. Infection-induced SARS-CoV-2 Seroprevalence among blood donors, Japan, 2022. Emerg Infect Dis. 2023;29(9):1868–71. doi:10.3201/eid2909.230365.
  • Kanamori R, Yan Y, Ito K, Fukuda H, Hori S, Yamamoto T, Igawa G, Saito K, Horiuchi Y, Nojiri S, et al. Increased SARS-CoV-2 seroprevalence and spread of infection without awareness among healthcare workers through 2020–2022 in a Japanese medical center. Sci Rep. 2023;13(1):4941. doi:10.1038/s41598-023-32193-4.
  • Fukuda H, Seyama K, Ito K, Ai T, Nojiri S, Hori S, Wakita M, Saito K, Shida Y, Nagura R, et al. SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo. Sci Rep. 2021;11(1):8380. doi:10.1038/s41598-021-87688-9.
  • Igawa G, Ai T, Yamamoto T, Ito K, Nojiri S, Saito K, Wakita M, Fukuda H, Hori S, Misawa S, et al. Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a university hospital at Tokyo. Sci Rep. 2022;12(1):8707. doi:10.1038/s41598-022-12809-x.
  • Noda K, Matsuda K, Yagishita S, Maeda K, Akiyama Y, Terada-Hirashita J, Matsushita H, Iwata S, Yamashita K, Atarashi Y, et al. A novel highly quantitative and reproducible assay for the detection of anti‑SARS‑CoV‑2 IgG and IgM antibodies. Sci Rep. 2021;11(1):5198. doi:10.1038/s41598-021-84387-3.
  • Koerber N, Priller A, Yazici S, Bauer T, Cheng CC, Mijočević H, Wintersteller H, Jeske S, Vogel E, Feuerherd M, et al. Dynamics of spike-and nucleocapsid specific immunity during long-term follow up and vaccination of SARS-CoV-2 convalescents. Nat Commun. 2022;13(1):153. doi:10.1038/s41467-021-27649-y.
  • EUA Authorized Serology Test Performance. 2022. [accessed 2023 Aug 19]. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance.
  • VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-Value. Ann Intern Med. 2017;167(4):268–74. doi:10.7326/M16-2607.
  • Arbel R, Peretz A, Sergienko R, Friger M, Beckenstein T, Duskin-Bitan H, Yaron S, Hammerman A, Bilenko N, Netzer D, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis. 2023;23(8):914–21. doi:10.1016/S1473-3099(23)00122-6.
  • Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, Yanai A, Arioka H, Uehara Y, Ihara G, et al. Effectiveness of BA.1- and BA.4/BA. 5-containing Bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan. Open Forum Infect Dis. 2023;10(6):ofad240. doi:10.1093/ofid/ofad240.
  • Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahne SJ, den Hartog G, van de Wijgert JH, van den Hof S, Knol MJ. Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022. Euro Surveill. 2023;28(7):2300087. doi:10.2807/1560-7917.ES.2023.28.7.2300087.
  • Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, Gallup L, Rowe M, Schonberg E, Thai S, et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N Engl J Med. 2023;388(6):565–7. doi:10.1056/NEJMc2213948.
  • Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L, Ho DD. Antibody response to Omicron BA.4–BA.5 bivalent booster. N Engl J Med. 2023;388(6):565–7. doi:10.1056/NEJMc2213907.
  • Marking U, Bladh O, Aguilera K, Yang Y, Norin NG, Blom K, Hober S, Klingström J, Havervall S, Åberg M, et al. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden. Lancet Infect Dis. 2024;24(2):80–1. doi:10.1016/S1473-3099(23)00779-X.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.